DOCSLIB.ORG

American Made 2.0

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
American Made 2.0 American Made 2.0 How Immigrant Entrepreneurs Continue to Contribute to the U.S. Economy by Stuart Anderson NATIONAL FOUNDATION FOR AMERICAN POLICY NATIONAL VENTURE CAPITAL ASSOCIATION About the Study This study commissioned by the National Venture Capital Association was prepared by Stuart Anderson, Executive Director, National Foundation for American Policy, a non-profit, non-partisan public policy research organization. 2 Contents Executive Summary 4 Section I: Immigrant-Founded Public and Privately-Held 10 Venture-Funded Companies Section II: Private Company Perspectives on U.S. 18 Immigration Policy Section III: U.S. Immigration Policy and Proposed Changes to 21 the Immigration System Conclusion 27 About the Author 28 Endnotes 29 3 Executive Summary Entrepreneurs are the heroes of a market-based economy, driving innovation and job creation. This NVCA study shows if entrepreneurs are indeed heroes, then immigrant entrepreneurs have made heroic contributions to America’s economy. The analysis concludes the contributions of immigrants to the United States would be even greater if Congress adopted the right policies on startups and high skill immigration. In 2006, the National Venture Capital Association released American Made: The Impact of Immigrant Entrepreneurs and Professionals on U.S. Competitiveness. It received significant attention as the first study to examine the role of immigrants in starting venture-funded companies. The study found immigrants started many U.S. venture-backed companies that became publicly traded and that these companies had achieved a significant market value, representing a benefit to the American economy, employees and investors. The new study used the Thomson Reuters database and performed extensive research to determine the nativity of the founders of U.S. venture-funded companies that became publicly traded between 2006 and 2012. It also updated data on companies with initial public offerings prior to 2006. In addition, privately-held venture-backed companies were surveyed for their views on current immigration policy and potential reforms to the immigration system. The report is divided into three sections. The first section analyzes and presents data on immigrant founders of publicly traded venture-funded companies. The second section presents the results of an NVCA survey of privately-held companies. The final section discusses U.S. immigration policy and innovation. The study also contains profiles of outstanding immigrant founders of venture-backed companies. 4 American Made 2.0 – Executive Summary Key Findings Immigrant-Founded Public Venture- - Venture-backed public companies with Funded Companies at least one immigrant founder and the - Successful startup companies illustrate the largest market capitalization include increasing importance of immigrants to Google, Intel, eBay, Facebook, LinkedIn, the U.S. economy. Data on initial public SanDisk, Altera and Tesla Motors. LinkedIn, offerings (IPOs) show a sharp increase in the Facebook and Tesla all had their initial economic influence of immigrant founders: public offerings since 2010. The combined 20 percent of venture-funded companies market capitalization of immigrant-founded with an initial public offering prior to venture-backed companies with initial public January 1, 2006, had an immigrant founder. offerings between 2006 and 2012 exceeds But between 2006 and 2012, immigrants $167 billion. started 33 percent of U.S. venture-backed companies that became publicly traded, - Immigrant-founded venture-backed public a total of 92 such companies. Prior to companies employ approximately 600,000 1980, only 7 percent of U.S. publicly people worldwide, the majority in the traded venture-funded companies had an United States. The companies employ an immigrant founder or co-founder. average of 2,579 employees, with 457 the median number of employees per company. - Venture-funded companies with at least Among the largest employers on the list are one immigrant founder that went public Intel, Google, Sanmina, eBay, PAREXEL, between 2006 and 2012 include such well- and Yahoo!. Immigrant-founded companies known names as Facebook, LinkedIn, Zipcar that went public since 2006 employ 65,588 and Tesla Motors. people, with annual sales of over $17 billion. - The value created to date by immigrant- - Among all venture-backed publicly traded founded venture-backed companies is companies with immigrant founders 21 extraordinary. Venture-backed publicly percent had a founder from India, 10 traded immigrant-founded companies have percent from Taiwan, 10 percent from a total market capitalization of $900 billion Israel, 8 percent from the United Kingdom, (as of June 2013). If immigrant-founded 7 percent from Germany, and 6 percent venture-backed public companies were a each from Canada and France. Among the country, then the value of its stock exchange companies with an IPO since 2006, India would rank 16th in the world, higher than was the most common country of origin for the exchanges of Russia, South Africa founders, with the United Kingdom and and Taiwan. Germany next, followed by Taiwan, France, Canada and Israel. American Made 2.0 – Key Findings 5 - Among all venture-backed companies with - Thirty-three percent of the entrepreneurs an immigrant founder that became publicly in the survey were foreign-born, matching traded 57 percent were located in California, the proportion among venture-backed 16 percent in Massachusetts, 4 percent in companies with an initial public offering New Jersey, and the remainder in other since 2006. states. Almost half of the venture-backed publicly traded companies with immigrant - India was the most common country of founders with initial public offerings origin among the immigrant-founded since 2006 were located in California. venture-backed privately-held companies Massachusetts was the second most common with 20 percent of the total. The United headquarters, followed by Maryland, Kingdom was next with 15 percent, followed New York and Texas. by Canada with 11 percent, France, Israel and Germany. - Among companies that became publicly traded prior to 2006, 42 percent of - Forty percent of the immigrant founders immigrant-founded venture-backed public in the survey entered the United States as companies were in high-tech manufacturing, employment-sponsored immigrants, 38 24 percent in information technology, percent as international students, 13 percent 21 percent in life sciences, and the rest in as family-sponsored immigrants, and the rest professional/technical services, finance/ in another category. insurance, e-commerce and other services or manufacturing. - Sixty-one percent of the privately-held immigrant-founded companies held one or - For the immigrant-founded companies with more patents. an initial public offering between 2006 and 2012, the leading sector was biotechnology, - Software, with 41 percent, was the most representing 27 percent of the total. Software common industry among the privately-held was next with 19 percent, followed by venture-backed companies with immigrant semiconductors with 12 percent and medical founders responding to the NVCA survey, devices and equipment with 10 percent. followed by biotechnology (11 percent), Networking and equipment, along with IT services (9 percent), business services telecommunications, represented 6 percent (6 percent), consumer goods/services (5 of the total. percent), media/entertainment (5 percent) and energy/clean energy (5 percent). Immigrant-Founded Private Venture- Funded Companies - Thirty-six percent of the privately- To provide greater insight into privately-held venture- held venture-backed companies with backed companies, NVCA sent surveys on immigrant immigrant founders in the survey were entrepreneurs and immigration policy to venture located in California, 29 percent were in capital members, who then forwarded the surveys Massachusetts, 10 percent in New York, 5 to companies in which they have invested. NVCA percent in Pennsylvania and the rest in received over 600 responses. other states. 6 American Made 2.0 – Key Findings Private Company Perspectives on been exhausted before the end of the fiscal U.S. Immigration Policy year. Fifty-seven percent of the companies - Among all private company founders, both replied that “projects had been delayed native-born and foreign-born, 79 percent because of the lack of H-1B visas.” Forty- believed, “The process for a foreign-born three percent of the companies said the lack entrepreneur to enter and remain in the U.S. of H-1B visas influenced the company’s to start a business is too difficult.” decisions to place or hire more personnel in facilities located outside the United States. - According to the NVCA survey, 90 percent of both native-born and foreign-born - While those who oppose expanding H-1B company founders believe a startup visa temporary visas often argue they are category would benefit the U.S. economy. preventing the “outsourcing” of jobs to other Two-thirds of immigrant entrepreneurs countries, numerous companies say it is the replying to the survey said, “A startup visa current restrictions on H-1B visas that push category would have been helpful when jobs offshore. starting their company in the United States.” U.S. Immigration Policy and Proposed - The Ewing Marion Kauffman Foundation Changes to the Immigration System concluded a startup visa with an annual Reforms to U.S. immigration policy must address quota of 75,000 could create “nearly 1.6 four major problems for employers.
Load more

Recommended publications
  • Biochemistrystanford00kornrich.Pdf
    University of California Berkeley Regional Oral History Office University of California The Bancroft Library Berkeley, California Program in the History of the Biosciences and Biotechnology Arthur Kornberg, M.D. BIOCHEMISTRY AT STANFORD, BIOTECHNOLOGY AT DNAX With an Introduction by Joshua Lederberg Interviews Conducted by Sally Smith Hughes, Ph.D. in 1997 Copyright 1998 by The Regents of the University of California Since 1954 the Regional Oral History Office has been interviewing leading participants in or well-placed witnesses to major events in the development of Northern California, the West, and the Nation. Oral history is a method of collecting historical information through tape-recorded interviews between a narrator with firsthand knowledge of historically significant events and a well- informed interviewer, with the goal of preserving substantive additions to the historical record. The tape recording is transcribed, lightly edited for continuity and clarity, and reviewed by the interviewee. The corrected manuscript is indexed, bound with photographs and illustrative materials, and placed in The Bancroft Library at the University of California, Berkeley, and in other research collections for scholarly use. Because it is primary material, oral history is not intended to present the final, verified, or complete narrative of events. It is a spoken account, offered by the interviewee in response to questioning, and as such it is reflective, partisan, deeply involved, and irreplaceable. ************************************ All uses of this manuscript are covered by a legal agreement between The Regents of the University of California and Arthur Kornberg, M.D., dated June 18, 1997. The manuscript is thereby made available for research purposes. All literary rights in the manuscript, including the right to publish, are reserved to The Bancroft Library of the University of California, Berkeley.
    [Show full text]
  • Woody Powell
    Note to readers: Please do not be alarmed by the length. There is a 48 page Appendix. You may want to print only the paper itself, pp. 1- 66. We would, however, welcome reactions to the Appendix and thoughts on how and whether to present the case materials. Chance, Necessité, et Naïveté: Ingredients to create a new organizational form* Walter W. Powell Kurt Sandholtz Stanford University January, 2010 *The title comes from remarks by Genentech co-founder Herbert Boyer (2001: 95-96): “I think if we had known about all the problems we were going to encounter, we would have thought twice about starting. I once gave a little talk to a group at a Stanford Business School luncheon, and I took off on the title of a book on evolution by Jacques Monod…Chance et Necessité. The title of my talk was ‘Chance, Necessité, et Naïveté.’ Naïveté was the extra added ingredient in biotechnology.” We thank Tricia Soto, librarian at the Center for Advanced Study in the Behavioral Sciences, and Tanya Chamberlain for assistance in finding archival materials. Martin Kenney was most generous in providing us with the source documents he used in writing his 1986 book, one of the very first studies of the development of the biotechnology industry. Our thanks to the Center for Advanced Study for hosting Professor Powell while the chapter was prepared. We are grateful to Pablo Boczkowski, Ron Burt, John Padgett, members of the Networks and Organizations Workshop at Stanford, and the Organizations and Markets workshop at the University of Chicago for comments on our initial draft.
    [Show full text]
  • Top 100 Living Contributors to Biotechnology
    Over the last 30 years, a small group of visionaries in science, technology, legislation and business have driven the development of biotechnology. THE Today, in the midst of tremendous advances in medicine and agriculture, this exhibition and accompanying brochure pays tribute to the leaders that have shaped the biotechnology industry. TOP The Top 100 Living Contributors to Biotechnology have been selected by their peers and through independent polls conducted by Reed Exhibitions, a division of Reed Elsevier. Senior staff throughout the biotechnology industry have identified the most influential and inspirational pioneers. The results 100 are presented here alphabetically. LIVING CONTRIBUTORS To those named in the Top 100, and the many other contributors not listed, TO BIOTECHNOLOGY the biotechnology community is deeply appreciative. P 1 4 MICHAEL ASHBURNER SEYMOUR BENZER PAUL BERG Michael Ashburner is Professor Seymour Benzer instilled the Paul Berg is Cahill Professor in of Biology at the University of fundamental idea that genes Cancer Research, Emeritus, at Cambridge where he received his control behaviour. He began his the Stanford University School undergraduate degree and PhD, career studying gene structure of Medicine, and director emeri- both in genetics. Ashburner’s and code, developing a method tus of the Beckman Centre for current major research interests to determine the detailed struc- Molecular and Genetic are the structure and evolution of ture of viral genes in 1955. He Medicine. He is one of the prin- genomes. Most of his research then switched to the field of cipal pioneers in the field of 33 has been with the model organ- neurogenetics, focusing on “gene splicing.” Berg, along with ism Drosophila melanogaster, the inheritance of behaviour.
    [Show full text]
  • Alexza Pharmaceuticals 2006 Annual Report
    vs. Alexza Pharmaceuticals 2006 Annual Report vs. fast delivery With many medical conditions, speed of treatment is critical. Episodes of these “acute and intermittent” conditions—such as migraine headaches, panic attacks, breakthrough pain, agitation, and more— can quickly become debilitating. Alexza’s Staccato® system provides needed medication as fast as an injection. With just one breath, patients receive a dose of pure aerosolized drug—deep into their lungs—where it is quickly absorbed into the blood stream to begin providing therapeutic effect. vs. easy to use Using a Staccato device is as simple and intuitive as breathing. Doses are pre-set and there are no controls to deal with. About the size of a cell phone, the device fits easily in a pocket or purse. Patients don’t need to learn how to use the Staccato device—it is intuitive—nor do they have to rely on a caregiver to administer their medication. When the need arises, even unexpectedly, one breath is all it takes. 2 vs. more consistent Other inhalation drug delivery methods add fillers and excipients to the therapeutic compound. The proprietary Staccato system uses pure drug layered as a thin film on a substrate. The substrate heats rapidly when triggered by a patient inhalation. The drug instantly vaporizes and condenses into aerosol particles ranging from 1 to 5 microns in diameter—the optimal size to reach the highly vascular tissue of the deep lung for absorption into the blood stream. And the system produces a consistently high emitted dose regardless of the patient’s breathing pattern. 4 vs.
    [Show full text]
  • Dear Arthur, Roger, Tom, Ken, Welcome to Tokyo! Kornberg Family Photo in 1959, Stockholm Roger Ken Sylvy Arthur Tom
    Toward innovative research: Lessons from the Kornbergs July 23, 2007 Yasuda Auditorium Introduction by Ken-ichi Arai Kornberg Family Photo in 2006, Stockholm Dear Arthur, Roger, Tom, Ken, welcome to Tokyo! Kornberg Family Photo in 1959, Stockholm Roger Ken Sylvy Arthur Tom Sylvy discovered the enzyme that makes huge polyphosphate chains. Her high intelligence led to key insights at many stages of our work on replication. For the Love of Enzymes The Odyssey of a Biochemist Arthur published books; DNA Replication, For the Love of Enzymes, Golden Helix (Inside Biotech Ventures). This book is a modern-day “Book of Five Rings” that replaces the medium of Swordmanship with that of biochemistry, particularly enzymology. In relating his story, Kornberg never avoids the difficult question of why? Joining the Enzyme Hunters: Arthur’s Mentors Gerty & Carl Cori in 1947 Gerty had no faculty appointment until 1947 when she shared the Nobel Prize Severo Ochoa in 1955 with Carl. I had come to the Cori laboratory to solve the major problem in I went to New York to meet Ochoa. He biochemistry, the mechanism of aerobic agreed to take me and I started as his phosphorylation. first postdoctoral student a month later. Arthur Kornberg Network S. Ochoa NYU, USA A. Kornberg O. Hayaishi Stanford, USA Kyoto A. Kornberg, Y. Kaziro, O. Hayaishi, R.& T. Okazaki C. Weissmann K. Ueda, K. & N. Arai Y. Nishizuka, K. Ueda, T. Honjo H. Okayama, T. Shimizu P. Berg Stanford, USA C. Weissmann Y. Kaziro R.&T. Okazaki H. Okayama Zurich, Swiss IMSUT Nagoya R. Mulligan T. Tadatsugu, K.& N.
    [Show full text]
  • Learning Outcomes
    General Catalog 2014 - 2015 TABLE OF CONTENTS Academic Calendar ..................................... 3 Undergraduate Academic Information ................................................... 60 Introduction to NDNU ............................. 5 Undergraduate Degrees ............................ 60 President’s Welcome ................................. 5 Undergraduate Policies and Mission Statement ..................................... 6 Procedures ......................................... 78 Vision Statement ....................................... 6 History of NDNU .................................... 6 Graduate General Regulations ................ 95 Academic Freedom Statement ................ 7 Statement of Nondiscrimination ............ 7 College of Arts and Sciences .................... 107 Accreditation .............................................. 8 Art/Art and Graphic Design ................. 107 Nature of Catalog ...................................... 8 Art Therapy Psychology ......................... 111 Clinical Psychology ................................. 118 Office of the Provost ................................... 10 Computer and Information Academic Affairs ....................................... 10 Science ................................................ 127 Student Affairs ........................................... 10 English ...................................................... 132 University Services .................................... 10 English for International Organizations, Activities, and Events .... 15 Students
    [Show full text]
  • Early Days of Syntex Life After Syntex Continued from Page 8 Continued from Page 9
    23-2 CHF 2005 9/8/05 2:45 PM Page 8 George Rosenkranz (center) displays a test tube of yam-derived diosgenin, the substance needed to produce steroid hormones, and its raw source material, Mexican yams. Grouped around him from left to right are Alex Nussbaum, Mercedes Velasco, Gilbert Stork, Jan Pataki, Enrique Batres, Juan Berlin, Carl Djerassi, Rosa Yashin, Octavio Mancera, Jesùs Romo. CHF Collections. Courtesy of Roche. LifeLife afterafter SyntexSyntex By Alejandro Zaffaroni Early Years of age. My father was in the banking business, Alejandro Zaffaroni at My life started in Montevideo, Uruguay, many and our family enjoyed a good standard of living. CHF in 2004. Photo by years ago. Uruguay is a small country; today Early in my life, I lost both my parents. My Steven Begleiter. it has three million people. Back then life in mother passed away when I was 12 years of age, Uruguay was wonderful. It was a great place to and my father when I was 18. Now, when I look live—safe and peaceful—and the standard of back, I think that loss forced me to learn to be on living was high. For many years, Uruguay was my own. I was also lucky enough to have an uncle known as the Switzerland of South America. and an older sister who supported and encour- The social and political organizations were aged me to continue my education. very progressive: women were allowed to vote; After earning a B.Sc. at the University of it had the highest rates of literacy; it was the Montevideo in 1941, I began studying at the first social democracy on the continent; pri- school of medicine.
    [Show full text]
  • 1.01 Reflections of a Medicinal Chemist
    1.01 Reflections of a Medicinal Chemist: Formative Years through Thirty-Seven Years Service in the Pharmaceutical Industry R F Hirschmann, University of Pennsylvania, Philadelphia, PA, USA J L Sturchio, Merck & Co., Inc., Whitehouse Station, NJ, USA & 2007 Elsevier Ltd. All Rights Reserved. 1.01.1 Introduction 2 1.01.2 The Training of a Medicinal Chemist 2 1.01.2.1 Graduate School 2 1.01.2.2 My 37 Years At Merck & Co., Inc. 3 1.01.2.2.1 The cortisol era 3 1.01.2.2.2 Transfer to exploratory research 8 1.01.3 The Merger Between Merck & Co., Inc. and Sharp & Dohme 11 1.01.3.1 Transfer to West Point, PA 12 1.01.3.1.1 Compounds possessing two symbiotic biological activities 13 1.01.3.1.2 Methyldopa progenitors 13 1.01.3.1.3 The somatostatin program 14 1.01.3.1.4 The protease inhibitor program 14 1.01.4 P. Roy Vagelos, MD, Successor to Dr L. H. Sarett 15 1.01.4.1 A New Assignment: Vice President of Basic Research 16 1.01.4.2 A Breakthrough at the Squibb Institute of Medical Research 16 1.01.4.3 Improved Second-Generation Converting Enzyme Inhibitors 17 1.01.4.4 The Concept of ‘The Champion’ in Drug Discovery: Benign Prostatic Hypertrophy and the Inhibition of 5a-Reductase 17 1.01.4.5 Hypercholesterolemia: A Challenge for the Pharmaceutical Industry 18 1.01.4.5.1 A breakthrough at Sankyo: the discovery of compactin 18 1.01.4.5.2 The discovery of the first approved b-hydroxy-b-methylglutaryl-CoA reductase inhibitor, lovastatin 19 1.01.4.5.3 The discovery of simvastatin 19 1.01.4.5.4 Lipitor 19 1.01.4.5.5 A new mechanism to lower plasma cholesterol
    [Show full text]